Research location

Qingdao

China

Published trials125

Site observations135

Linked trials published125

Page1 / 3

Research activity in Qingdao

China

CureCurrent currently publishes aggregate city-level research activity for this location: 125 trials and 135 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Qingdao

125 linked trials · page 1 of 3

Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving Heart Failure With Preserved Ejection FractionNCT07693049 · 2026-08-10 · 1 site observation

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusNCT07662044 · 2026-07-06 · 1 site observation

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMNCT07667803 · 2026-06-29 · 1 site observation

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm StudyNCT07295821 · 2026-04-01 · 1 site observation

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)NCT07111520 · 2025-09-22 · 1 site observation

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic PhenotypeNCT07190222 · 2025-09-17 · 1 site observation

Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRTNCT07309211 · 2025-07-08 · 1 site observation

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT07082738 · 2025-06-27 · 1 site observation

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationNCT06959095 · 2025-06-20 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · 2025-04-10 · 1 site observation

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsNCT06932263 · 2025-03-26 · 1 site observation

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)NCT06883305 · 2025-03-18 · 1 site observation

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET AmplificationNCT07322783 · 2025-01-01 · 1 site observation

Digital Early Warning System for Acute Lung Injury in Liver SurgeryNCT07070362 · 2024-11-01 · 1 site observation

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With AsthmaNCT06471257 · 2024-06-17 · 1 site observation

Phase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 2024-02-28 · 1 site observation

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 1 site observation

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)NCT06210776 · 2024-01-15 · 1 site observation

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerNCT05950945 · 2023-12-30 · 1 site observation

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsNCT06079983 · 2023-12-01 · 1 site observation

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)NCT06095583 · 2023-11-15 · 1 site observation

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationNCT05696626 · 2023-10-31 · 2 site observations

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLCNCT05536505 · 2022-09-13 · 1 site observation

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionNCT05179876 · 2022-05-04 · 1 site observation

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsNCT04930432 · 2021-09-24 · 2 site observations

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 2 site observations

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaNCT06666855 · 2024-11-28 · 1 site observation

ACTIVE_NOT_RECRUITING

An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma PatientsNCT06605885 · 2024-11-14 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06711900 · 2024-10-30 · 1 site observation

ACTIVE_NOT_RECRUITING

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsNCT06635447 · 2024-09-26 · 1 site observation

ACTIVE_NOT_RECRUITING

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of ExacerbationsNCT06529419 · 2024-08-30 · 1 site observation

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaNCT06502366 · 2024-07-22 · 1 site observation

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung CancerNCT06984588 · 2024-03-28 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In ChinaNCT06422663 · 2024-03-22 · 1 site observation

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DMNCT06327815 · 2024-03-15 · 1 site observation

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic AsthmaNCT06465485 · 2024-02-28 · 1 site observation

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaNCT06097728 · 2023-11-09 · 1 site observation

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsNCT06040086 · 2023-09-22 · 1 site observation

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCNCT05844150 · 2023-06-01 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNCT05840211 · 2023-05-08 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.NCT05763121 · 2023-01-30 · 1 site observation

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903NCT06846099 · 2022-12-07 · 1 site observation

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)NCT05629585 · 2022-11-28 · 1 site observation

ACTIVE_NOT_RECRUITING

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.NCT05562934 · 2022-11-08 · 1 site observation

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyNCT05450692 · 2022-09-15 · 1 site observation

ACTIVE_NOT_RECRUITING

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentNCT05261399 · 2022-08-03 · 1 site observation

ACTIVE_NOT_RECRUITING

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)NCT05413369 · 2022-07-07 · 1 site observation

Roll-over Study to Allow Continued Access to RibociclibNCT05161195 · 2022-07-07 · 1 site observation

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal PolypsNCT05274750 · 2022-04-22 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.